Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00702572 · ClinicalTrials.gov registry record · Phase 1
Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Milton S. Hershey Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00702572 is a Phase 1 study that was terminated before completion, run by Milton S. Hershey Medical Center. The registered enrollment target is 25 participants.
The verdict
NCT00702572, a Phase 1 study, was terminated before completion, sponsored by Milton S. Hershey Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The primary objective of the study is to establish the phase II recommended dose of Vorinostat when administered in combination with the regimen of carboplatin, paclitaxel and bevacizumab for patients with previously untreated advanced non-small cell lunc cancer.
Interventions
- DRUG Vorinostat, Bevacizumab, Carboplatin, Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-04 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00702572
The ClinicalTrials.gov registry entry for NCT00702572 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vorinostat, Bevacizumab, Carboplatin, Paclitaxel is the first listed.
NCT00702572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00702572 about?
NCT00702572 is a clinical study titled "Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer". The primary objective of the study is to establish the phase II recommended dose of Vorinostat when administered in combination with the regimen of carboplatin, paclitaxel and bevacizumab for patients with previously untreated advanced non-small cell lunc cancer.
What is the current status of trial NCT00702572?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2008-04. Estimated completion is 2016-09.
What interventions are being tested in trial NCT00702572?
The interventions under investigation include: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00702572?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.